Putative repurposing of lamivudine, a nucleoside/nucleotide analogue and antiretroviral to improve the outcome of cancer and COVID-19 patients

JJ García-Trejo, R Ortega, M Zarco-Zavala - Frontiers in Oncology, 2021 - frontiersin.org
Lamivudine, also widely known as 3TC belongs to a family of nucleotide/nucleoside
analogues of cytidine or cytosine that inhibits the Reverse Transcriptase (RT) of retroviruses …

Drug repurposing against COVID-19: focus on anticancer agents

G Ciliberto, R Mancini, MG Paggi - Journal of experimental & clinical …, 2020 - Springer
Background The very limited time allowed to face the COVID-19 pandemic poses a pressing
challenge to find proper therapeutic approaches. However, synthesis and full investigation …

[HTML][HTML] In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach

MI Zapata-Cardona, L Florez-Alvarez… - AIMS …, 2023 - ncbi.nlm.nih.gov
Background Drug repurposing is a valuable strategy for rapidly developing drugs for treating
COVID-19. This study aimed to evaluate the antiviral effect of six antiretrovirals against …

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

H Yousefi, L Mashouri, SC Okpechi, N Alahari… - Biochemical …, 2021 - Elsevier
The outbreak of a novel coronavirus (SARS-CoV-2) has caused a major public health
concern across the globe. SARS-CoV-2 is the seventh coronavirus that is known to cause …

[HTML][HTML] Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment

VP Chavda, N Gajjar, N Shah, DJ Dave - European Journal of Medicinal …, 2021 - Elsevier
Antivirals already on the market and expertise gained from the SARS and MERS outbreaks
are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS …

Comparison of antiviral activity of gemcitabine with 2′-fluoro-2′-deoxycytidine and combination therapy with remdesivir against SARS-CoV-2

Y Jang, JS Shin, MK Lee, E Jung, T An, UI Kim… - International journal of …, 2021 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the coronavirus disease 2019 (COVID-19) pandemic. The virus still spreads globally through …

[PDF][PDF] Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?

P Gougis, C Fenioux, C Funck-Brentano, M Veyri… - European Journal of …, 2020 - Elsevier
The rapid emergence of COVID-19 pandemics worldwide is of particular concern for fragile
populations who are more at risk of acute respiratory distress syndrome and death. Patients …

Repurposing FDA-approved drugs targeting SARS-CoV2 3CLpro: a study by applying virtual screening, molecular dynamics, MM-PBSA calculations and Covalent …

IJ Santos Nascimento, TM Aquino… - Letters in Drug …, 2022 - ingentaconnect.com
Background: Since the end of 2019, the etiologic agent SAR-CoV-2 responsible for one of
the most significant epidemics in history has caused severe global economic, social, and …

The first Chinese oral anti-COVID-19 drug Azvudine launched

B Yu, J Chang - The Innovation, 2022 - cell.com
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at
the end of 2019, thousands of SARS-CoV-2 mutations have been increasingly observed …

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis

R Alexpandi, JF De Mesquita, SK Pandian… - Frontiers in …, 2020 - frontiersin.org
The novel coronavirus SARS-CoV-2 disease “COVID-19” emerged in China and rapidly
spread to other countries; due to its rapid worldwide spread, the WHO has declared this as a …